Calidi Biotherapeutics, Inc.
CLDI
$1.59
$0.053.25%
AMEX
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | 4.40% | 10.10% | 24.08% | 14.60% | 33.61% |
| Total Depreciation and Amortization | 8.23% | 7.56% | 7.64% | 8.42% | 7.46% |
| Total Amortization of Deferred Charges | -- | -- | 101.68% | 128.26% | -88.26% |
| Total Other Non-Cash Items | -29.55% | -33.58% | 5.22% | 189.67% | -59.78% |
| Change in Net Operating Assets | 65.04% | -179.33% | -254.38% | -42.31% | -53.40% |
| Cash from Operations | 20.51% | -8.12% | -11.38% | 20.15% | 17.01% |
| Capital Expenditure | -555.56% | -650.00% | -18.52% | 48.98% | 96.03% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -833.33% | -962.50% | -108.70% | 27.18% | 94.80% |
| Total Debt Issued | -- | -- | -100.00% | -81.25% | -85.37% |
| Total Debt Repaid | 75.41% | -32.31% | 40.35% | 49.62% | -49.72% |
| Issuance of Common Stock | -63.71% | -27.16% | 222.38% | 393.72% | 32,846.00% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 40.16% | 27.67% | 20.26% | -71.28% | 26.82% |
| Cash from Financing | -55.30% | -36.20% | 167.45% | -0.37% | 14.84% |
| Foreign Exchange rate Adjustments | 123.33% | 207.69% | 145.83% | -237.50% | -372.73% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -141.72% | -152.21% | 202.78% | 451.06% | 4,104.46% |